Esin KOTİLOĞLU, Handan KAYA, Saime SEZGİN, Gülsün EKİCİOĞLU

THE ROLE OF BASIC FIBROBLAST GROWTH FACTOR RECEPTOR (bFGF) AND C-KIT RECEPTOR IN PROGRESSION OF CUTANEOUS MELANOCYTIC LESIONS

Objective: We investigated the expression of basic Fibroblast Growth Factor (bFGF) and c-kit proto-oncogene in progression to malignancy and métastasés of melanocytic lesions.Methods: Immunohistochemical detection of bFGF and c-kit receptors were performed by peroxidase- antiperoxidase (PAP) technique on compound nevi, vertical growth phase malignant melanoma and metastatic malignant melanoma in 12, 12 and 15 cases respectively.Clinicopathological correlations were analysed by Paerson’s Chi-Square, Student’s T-Test and One Way Anova test.Results: bFGF receptor immunoreactivity rates were 83.3%, 83.3% and 80 % in compound nevi, primary MMs and metastatic MMs respectively, c-kit immunoreactivity was absent in nevus cells, but faintly present in 16.6 % (2 cases) of MM cells.Conclusion: The results of our study suggest that loss of c-kit expression is more important in dermal penetration than métastasés in melanomas.However, bFGF is not shown to be a prognostic factor for MMs.Key Words: c-kit, bFGF, Melanocytic nevi, Malignant melanoma, Metastatic melanoma

PDF

___

Alberts B, Bray D, Lewis J, Raff M, Roberts R, Watson JD. Molecular Biology of the Cell. 2nd ed. London: Garland Publishing, Inc. 1989: 681-790.
flerlyn M, Mandanti ML, Jambrosic J, Bolen JB, Koprowski ft. Regulatory factors that determine growth and phenotype of normal human melanocytes. Exp Cell Res ¡988; I 79: 322-331.
Shih IM, flerlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo 1994; 8:1 13-123.
lialaban R, Pan B, Ahn J, Punasaka Y, Gitay- Goren fl, Heufeld G. Growth factors, receptor kinases, and protein tyrosine phosphatases innormal and malignant melonocytes. J
Immunother 1992; 12:154-161.
Halaban R. Growth factors and tyrosine protein kinases in normal and malignant melanocytes. Cancer Metastasis Rev 1991; 10: 129-140.
Huang S, Luca M, Gutman M, et al. Enforced c- kit expression renders highly metastatic human melanoma cells susceptible to stem cell factor induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 1996; 13: 2339-2347.
Zakut R, Pedis R, Eliyahu S, et al. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 1993; 8: 2221-2229.
Tsuura Y, Hiraki H, Watanabe K, et af Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin- fixed- paraffin-embedded tissues. Virchows Arch 1994; 424: 135-141.
Al-Alousi S, Barnhill R, Blessing K, Barksdale S. The prognostic significance of basic fibroblast growth factor in cutaneous malignant melanoma. J Cutan Pathol 1996; 23: 506-510.
Luo D, Chen H, Searles Cj, Jumbow K. Coordinated mRHA expression of c-Kit with tyrosinase and TRP-1 in melanine pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/SCP-R. Melanoma Res 1995; 5: 303-309.
I I. Hatali PG, nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992; 52: 197-201.
Yarden Y, Kuang WJ, Yang-Peng T, et af Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1988; 7:1003- 1011.
Giebel LB, Strunk KM, Holmes 5/1, Spritz RA. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. Oncogene 1992;7:2207-221 7.
Hiroto S, Isozaki K, Moriyama Y, et al. Gain of function mutation of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580
Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD 117) in human tissues: Value in the diagnosis of mast cell disorders. Hum Pathol 1998; 28: 498-504.
Ohashi A, Funasaka Y, Ueda M, Ichihashi M. C- kit receptor expression in cutaneous malignant melanoma and benign melanocytic naevi. Melanoma Res 1996; 6: 25-30.
Lu C, Kerbel RS. Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr Opin Oncol 1994; 6: 212- 220.
Moretti S, Pinzi C, Spallanzani A, et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999; 84: 160-168.
Takahashi H, Saitoh K, Kishi H, Parsons PG. Immunohistochemical localisation of stem cell factor (SCP) with comparison of its receptor c-Kit proto-oncogene product (c-KIT) in melanocytic tumours. Virchows Arch 1995;427:283-288.
Welker P, Schadendorf D, Artuc M, Grabbe J, Llenz BM. Expression of SCP splice variants in human melonocytes and melanoma cell lines: potential prognostic implications. Br J Cancer 2000:82: 1453-1458.
Papadimitriou CA, Topp MS, Serve H, et al. Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines. Eur J Cancer 1995; 31 A: 2371-2378.
Salama S, Sircar K, Hewlett R. Kit expression in melanocytic lesions: An analysis of conventional nevi, Spitz and Reed's nevi, and melanoma. Am J Dermatopathol 1999; 21 : 595. (Abstracts : Joint Meeting of ISD)
Shin EY, Lee BH, Yang JH, et al. Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer.J Cancer Res Clin Oncol 2000;126:519-528.
Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer.Cancer Res 2000;60:4245-4250.
Shemirani B,Crowe DL. Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol 2000; 36: 61-66.
Alanko T, Rosenberg M, Saksela O. PGP expression allows nevus cells to survive in
7
Esin Kotiloglu, et al
three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. J Invest Dermatol 1999; 113: 111-116.
Meier F, Hesbit M, Hsu MY, et al. Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol 2000; 156: 193-200.
Ahmed HU, Ueda M, lto A, Ohashi A, Funasaka Y, Ichihashi M. Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res 1997; 7: 299-305.
Yaguchi H, Tsuboi R, Ueki R, Ogawa 11. Immunohistochemical localization of basic fibroblast growth factor in skin diseases. Acta Derm Venereol 1993; 73: 81-83.
Birck A, Firkin AF, Zeuthen J, Hou-Jensen F. Expression of basic fibroblast growth factor
and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 1999; 9: 375- 381.
Xerri L, Battyani Z, Grob JJ, et al. Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res 1996; 6:223-230.
Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Hat Med 1997; 3: 887-893.
Rofstad EF, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma